Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects
- PMID: 28700655
- PMCID: PMC5507312
- DOI: 10.1371/journal.pone.0181086
Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects
Abstract
Fatigue is the symptom most commonly reported by long-term cancer survivors and is increasingly recognized as related to skeletal muscle dysfunction. Traditional chemotherapeutic agents can cause acute toxicities including cardiac and skeletal myopathies. To investigate the mechanism by which chemotherapy may lead to persistent skeletal muscle dysfunction, mature adult mice were injected with a single cyclophosphamide dose and evaluated for 6 weeks. We found that exposed mice developed a persistent decrease in treadmill running time compared to baseline (25.7±10.6 vs. 49.0±16.8 min, P = 0.0012). Further, 6 weeks after drug exposure, in vivo parameters of mitochondrial function remained below baseline including maximum ATP production (482.1 ± 48.6 vs. 696.2 ± 76.6, P = 0.029) and phosphocreatine to ATP ratio (3.243 ± 0.1 vs. 3.878 ± 0.1, P = 0.004). Immunoblotting of homogenized muscles from treated animals demonstrated a transient increase in HNE adducts 1 week after exposure that resolved by 6 weeks. However, there was no evidence of an oxidative stress response as measured by quantitation of SOD1, SOD2, and catalase protein levels. Examination of mtDNA demonstrated that the mutation frequency remained comparable between control and treated groups. Interestingly, there was evidence of a transient increase in NF-ĸB p65 protein 1 day after drug exposure as compared to saline controls (0.091±0.017 vs. 0.053±0.022, P = 0.033). These data suggest that continued impairment in muscle and mitochondria function in cyclophosphamide-treated animals is not linked to persistent oxidative stress and that alternative mechanisms need to be considered.
Conflict of interest statement
Figures
Similar articles
-
Pioglitazone ameliorates the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice.Eur J Pharmacol. 2014 Oct 5;740:690-6. doi: 10.1016/j.ejphar.2014.06.008. Epub 2014 Jun 22. Eur J Pharmacol. 2014. PMID: 24964389
-
Loss of the antioxidant enzyme CuZnSOD (Sod1) mimics an age-related increase in absolute mitochondrial DNA copy number in the skeletal muscle.Age (Dordr). 2016 Aug;38(4):323-333. doi: 10.1007/s11357-016-9930-1. Epub 2016 Jul 21. Age (Dordr). 2016. PMID: 27444179 Free PMC article.
-
Skeletal muscle metabolic adaptations to endurance exercise training are attainable in mice with simvastatin treatment.PLoS One. 2017 Feb 16;12(2):e0172551. doi: 10.1371/journal.pone.0172551. eCollection 2017. PLoS One. 2017. PMID: 28207880 Free PMC article.
-
Skeletal muscle mitochondrial DNA deletions are not increased in CuZn-superoxide dismutase deficient mice.Exp Gerontol. 2015 Jan;61:15-9. doi: 10.1016/j.exger.2014.11.012. Epub 2014 Nov 20. Exp Gerontol. 2015. PMID: 25449857 Free PMC article.
-
Effect of lifelong resveratrol supplementation and exercise training on skeletal muscle oxidative capacity in aging mice; impact of PGC-1α.Exp Gerontol. 2013 Nov;48(11):1311-8. doi: 10.1016/j.exger.2013.08.012. Epub 2013 Aug 29. Exp Gerontol. 2013. PMID: 23994519
Cited by
-
A Comprehensive Review of Cancer Drug-Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies.Curr Treat Options Oncol. 2024 Feb 19. doi: 10.1007/s11864-023-01175-z. Online ahead of print. Curr Treat Options Oncol. 2024. PMID: 38372853 Review.
-
A single chemotherapy administration induces muscle atrophy, mitochondrial alterations and apoptosis in breast cancer patients.J Cachexia Sarcopenia Muscle. 2024 Feb;15(1):292-305. doi: 10.1002/jcsm.13414. Epub 2024 Jan 6. J Cachexia Sarcopenia Muscle. 2024. PMID: 38183352 Free PMC article.
-
The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT).Geroscience. 2023 Dec;45(6):3529-3548. doi: 10.1007/s11357-023-00861-y. Epub 2023 Jul 18. Geroscience. 2023. PMID: 37462785 Free PMC article.
-
Skeletal muscle mitochondrial interactome remodeling is linked to functional decline in aged female mice.Nat Aging. 2023 Mar;3(3):313-326. doi: 10.1038/s43587-023-00366-5. Epub 2023 Mar 2. Nat Aging. 2023. PMID: 37118428 Free PMC article.
-
Elamipretide Improves ADP Sensitivity in Aged Mitochondria by Increasing Uptake through the Adenine Nucleotide Translocator (ANT).bioRxiv [Preprint]. 2023 Feb 3:2023.02.01.525989. doi: 10.1101/2023.02.01.525989. bioRxiv. 2023. PMID: 36778398 Free PMC article. Updated. Preprint.
References
-
- Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet. 2003;362:640–50. doi: 10.1016/S0140-6736(03)14186-4 - DOI - PubMed
-
- al-Majid S, McCarthy DO. Cancer-induced fatigue and skeletal muscle wasting: the role of exercise. Biol Res Nurs. 2001;2(3):186–97. doi: 10.1177/109980040100200304 - DOI - PubMed
-
- Banthia R, Malcarne VL, Roesch SC, Ko CM, Greenbergs HL, Varni JW, et al. Correspondence between daily and weekly fatigue reports in breast cancer survivors. J Behav Med. 2006;29(3):269–79. doi: 10.1007/s10865-006-9053-8 - DOI - PubMed
-
- Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, et al. Cancer-related fatigue. J Natl Compr Canc Netw. 2010;8(8):904–31. - PubMed
-
- Calvani R, Joseph AM, Adhihetty PJ, Miccheli A, Bossola M, Leeuwenburgh C, et al. Mitochondrial pathways in sarcopenia of aging and disuse muscle atrophy. Biol Chem. 2013;394(3):393–414. doi: 10.1515/hsz-2012-0247 - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
